Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 27, 2023

SELL
$34.84 - $43.54 $755,679 - $944,382
-21,690 Reduced 76.94%
6,500 $250,000
Q1 2023

May 02, 2023

BUY
$33.46 - $40.35 $943,237 - $1.14 Million
28,190 New
28,190 $1.01 Million
Q3 2022

Nov 02, 2022

SELL
$30.79 - $39.82 $28,018 - $36,236
-910 Reduced 6.93%
12,228 $441,000
Q2 2022

Aug 01, 2022

SELL
$25.44 - $35.16 $28,645 - $39,590
-1,126 Reduced 7.89%
13,138 $400,000
Q1 2022

May 04, 2022

BUY
$25.09 - $33.13 $168,579 - $222,600
6,719 Added 89.05%
14,264 $403,000
Q4 2021

Feb 07, 2022

BUY
$15.6 - $35.4 $117,702 - $267,093
7,545 New
7,545 $236,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.39B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.